Scientific Sessions 2027 / Abstracts
Call for Abstracts · Scientific Sessions 2027
Share Your Research
Present your work at the NLA’s 25th anniversary Scientific Sessions in Nashville, and be part of the science shaping the future of lipidology and cardiometabolic health.
Nov 16
the abstract portal opens
Abstract portal
Submissions open November 16, 2026
The submission window runs through January 8, 2027. Submissions that aren’t completed by the end of the window won’t be considered, so give yourself time to finish.
This button goes live when the portal opens.
Important dates
Key dates for Nashville
Opens Nov 16
Abstract submission
Nov 16 – Jan 8
2026 – 2027
Notification
Acceptance notification
Feb 8 – 12
2027
Deadline
Presenting author registration
Mar 12
2027
Opens Feb 5
Late-breaking submission
Feb 5 – 26
2027
New this year
For the first time, the NLA is accepting late-breaking abstracts for high-impact findings that weren’t available before the regular deadline.
Why submit
Put your research in the spotlight
01
Present at the 25th anniversary meeting
Share your work with the clinicians and scientists leading lipid care, in person in Nashville.
02
Compete for abstract awards
New this year, top abstract submissions are recognized at the Honors & Awards Ceremony.
03
Get published
Abstracts from registered, in-person presenting authors are included for publication.
Abstract formats
Two ways to submit
Choose the format that fits your work. Either way, keep it to 400 words or fewer.
400
words max
Original research
Structure your abstract in these sections:
Background/Synopsis
Objective/Purpose
Methods
Results
Conclusion
Case study
Structure your abstract in these sections:
Background/Synopsis
Case Description
Outcome
Discussion
Before you submit
Guidelines at a glance
Generic drug names
Use generic names only.
Encore research
Identify encore presentations, with the original date and location of presentation or publication.
Written in English
Proper grammar and spelling, at a standard suitable for publication.
Proofread first
No corrective review is allowed after submission, so check everything carefully.
Financial disclosures
Required for every author. Failure to disclose may result in withdrawal.
AI disclosure
Disclose any AI use on submission, or indicate that none was used.
Scientific Sessions 2026
Last year’s abstract presentations
The fine print
General information and policies
Please review these before you submit.
Questions? Contact abstracts@lipid.org or 904-309-6203.
Presenting author registration
To ensure an abstract is included for publication, the presenting author must register as an in-person Scientific Sessions attendee, not as a sponsor, exhibitor or any other registration type. Virtual abstract presentation is not allowed. Authors who aren’t NLA members must pay the non-member registration fee, or can apply for membership. The presenting author registration deadline is March 12, 2027. Register here.
Completing your submission
If an abstract submission isn’t completed and submitted by the end of the submission window, it will not be considered.
Authorship
Each author listed on the abstract should have made a substantial contribution to it, such as contributing to the conception and design of the study and the acquisition of data; analysis and interpretation of the data; and/or drafting the poster or revising it critically for important intellectual content.
Financial disclosures
Financial disclosures must be provided for each author. Any failure to disclose may result in an abstract being withdrawn from the NLA abstracts program.
AI disclosure
AI use must be disclosed upon submission. If no AI was used, that should also be indicated in your submission.
Copyright
Authors assign copyright of the abstract to the NLA upon submission. The author retains a non-exclusive, permanent license to the copyrighted material.
Selection process
How abstracts are reviewed
Blinded review
Submitted abstracts are reviewed in a blinded fashion by the NLA Abstract Review Committee and scored on three criteria.
01
Scientific merit
Direction toward the development of a new or improved diagnostic procedure or idea; facts and data have scientific backing; sound research design and analytical methodology.
02
Interest to the field
Relevance to lipidology and cardiometabolic health, and to the NLA’s mission “to enhance the science and practice of lipidology and promote optimal cardiometabolic health.”
03
Organization and presentation
Well written, clear, succinct and well organized; easy to follow and understand; shows understanding of the subject matter.
New this year
Late-breaking abstracts
The late-breaking category is a platform reserved for high-impact, transformative findings and decisive clinical trial results that weren’t available before the standard abstract deadline.
Late-breaking window
Feb 5 – 26
2027 submission window
Please note: The late-breaking window is not an extension of the regular abstract deadline.
What is a late-breaking abstract?
A late-breaking abstract highlights practice-changing, novel or urgent cardiometabolic and lipid science.
It is intended strictly for original work whose primary endpoints, definitive data or major scientific breakthroughs were generated, unblinded or concluded after the close of the regular submission deadline.
Eligible research types
Late-breaking consideration is typically given to:
• Primary outcome results of prospective, randomized controlled clinical trials (Phase II–IV)
• Major, definitive findings from large prospective registries or longitudinal cohorts
• High-impact translational, genomic or fundamental lipid science discoveries
• Unplanned, novel post-hoc analyses answering emergent therapeutic or public health questions
What qualifies
Truly novel findings: Definitive data and conclusive analyses that were finalized and locked after the regular submission cutoff.
Groundbreaking impact: Work with immediate implications for clinical practice, guideline development, drug development or the fundamental understanding of lipid biology.
Complete justification: All submissions must include the mandatory justification statement.
What does not qualify
Abstracts will be deemed ineligible and rejected without appeal if they are:
• Missed deadlines: Studies completed before the general abstract cutoff that simply missed the deadline
• Incremental or preliminary data: Studies whose initial or preliminary datasets were known before the standard deadline, with only minor additions or extended follow-up added
• Previously rejected work: Work submitted and rejected during the regular NLA abstract review cycle, or resubmissions with minor edits
• Case reports and case series: Clinical case reports and small, descriptive retrospective case series
• Previously published or presented: Studies published in a peer-reviewed journal (print or online ahead of print) or presented at another major national or international congress before the NLA Scientific Sessions
Mandatory justification statement
During submission, authors must complete a separate Late-Breaking Justification field. Submissions without it will not be reviewed. The justification must explicitly address:
• Timing: The exact date study data were unblinded, locked or statistical analyses finalized
• Rationale: Why the research could not have been submitted during the regular submission period
• Significance: Why the findings represent an urgent, groundbreaking contribution to clinical lipidology
Review process
All submissions undergo accelerated, blinded peer review. The review committee reserves the right to reject an abstract that lacks sufficient originality, fails to demonstrate late-breaking timing or omits the justification statement.
Rejected late-breaking abstracts will not be automatically converted or transferred to standard poster sessions.
Questions?
We’re here to help
For help with the abstract submission process, contact NLA staff at abstracts@lipid.org or 904-309-6203.
